Skip to content
Market Spectator

Market Spectator

Primary Menu
  • Business
  • Domestic
  • Economy
  • Politics
  • Top News
  • Newsletters
Live
  • Home
  • 2024
  • March
  • 6
  • Biden to call for expanding Medicare drug negotiation program
  • Domestic

Biden to call for expanding Medicare drug negotiation program

Market Spectator March 6, 2024 2 minutes read
U.S. President Biden hosts event on health care costs, Medicare

U.S. President Biden hosts event on health care costs, Medicare and Social Security at the White House to Washington

By Ahmed Aboulenein

WASHINGTON (Reuters) – President Joe Biden will call on Congress to expand the number of drugs subject to annual Medicare price negotiations in his State of the Union address on Thursday, the White House said.

The negotiation program, passed as part of 2022’s Inflation Reduction Act, empowers Medicare to use its vast size to bargain with pharmaceutical companies to lower prices of expensive drugs for Medicare participants, who are age 65 and older.

The program currently foresees adding 10 to 20 drugs a year through 2029, and Biden will propose increasing this to 50, White House domestic policy adviser Neera Tanden told reporters on a media call on Wednesday.

“Medicare should not be limited to negotiating just 10 drugs a year or 20 drugs a year. That is why the president will propose that Medicare should be able to negotiate prices for at least 50 drugs per year,” Tanden said.

Negotiations for the first 10 drugs in the program began last month with price changes set to take effect in 2026. Under the law that number grows by 15 per year in 2027 and 2028 then by 20 a year starting 2029.

Biden made a similar call last year but Congress did not take it up. Any amendment of the Inflation Reduction Act, which passed without a single Republican vote, would need approval from a divided Congress.

Drugmakers and industry groups have filed lawsuits challenging the program on several grounds, including claims that it takes away their property rights without due process, in violation of the U.S. Constitution, with courts upholding the law three times so far.

Biden has made lowering healthcare costs a key part of his 2024 reelection campaign and will call on Congress in his Thursday speech to expand other healthcare benefits outlined in the Inflation Reduction Act, the White House said.

He is proposing that a $2,000 cap on out-of-pocket prescription drug costs in Medicare, set to start in 2025, be expanded to include all private insurance, and that the law’s requirement that pharmaceutical companies pay rebates to Medicare when they increase drug prices faster than inflation apply to commercial drug sales as well.

Biden will also call on Congress to cap out-of-pocket costs for common generic drugs at $2 for people on Medicare.

(Reporting by Ahmed Aboulenein; Editing by Cynthia Osterman)

tagreuters.com2024binary_LYNXNPEK250TC-VIEWIMAGE

About the Author

Market Spectator

Administrator

View All Posts

Post navigation

Previous: BofA joins rivals in predicting stronger investment banking revenue
Next: Wall Street indexes advance as Fed’s Powell fuels hopes for rate cuts this year

Related Stories

Former U.S. President Trump's criminal trial on charges of falsifying
  • Domestic

Factbox-Who are the candidates running in the 2024 US presidential election?

Market Spectator May 9, 2024
FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns
  • Domestic

People with two copies of a risk gene have genetic form of Alzheimer’s, scientists say

Market Spectator May 6, 2024
FILE PHOTO: Supporters of former U.S. President Donald Trump wave
  • Domestic

Trump, RNC raise over $76 million in April, half from small donors

Market Spectator May 5, 2024

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Categories

  • Business
  • Domestic
  • Economy
  • Money
  • Politics
  • Top News
  • Uncategorized

Recent Posts

  • LLY and the GLP-1 Franchise: What the Options Market Knows That the Headlines Don’t
  • Palantir Is Not an AI Hype Story Anymore
  • Nvidia Just Printed $81.6 Billion and the Stock Went Down. Here’s What the Tape Is Really Telling You.
  • The Power Grid Is Cracking Under the Weight of AI. One Stock Is the Cleanest Way to Play It.
  • XLE and the Hormuz Premium: The Energy Sector’s Options Market Is Pricing a Regime Change

You may have missed

b7313fbf-ebed-483b-8254-22ed5e315625
  • Top News

LLY and the GLP-1 Franchise: What the Options Market Knows That the Headlines Don’t

Market Spectator May 29, 2026
74f93bfb-5a92-4b2f-830a-0a696325170a
  • Top News

Palantir Is Not an AI Hype Story Anymore

Market Spectator May 29, 2026
75962f66-78bc-409a-bdd2-0011e20d52ec
  • Business

Nvidia Just Printed $81.6 Billion and the Stock Went Down. Here’s What the Tape Is Really Telling You.

Market Spectator May 29, 2026
a5c94683-cbfe-41aa-936a-afe53ef20b1d
  • Business

The Power Grid Is Cracking Under the Weight of AI. One Stock Is the Cleanest Way to Play It.

Market Spectator May 29, 2026
  • Home
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Contact Us
Copyright 2026 © All rights reserved | Market Spectator | marketspectator.com SITE_OK